U.S. Industrials Stock News

In early March 2026, ADT Inc. announced a share repurchase program of up to US$1.50 billion running through April 30, 2029, alongside fourth-quarter 2025 results showing revenue of US$1,276 million and net income of US$145 million, plus a US$0.055 per-share dividend payable on April 2, 2026. At the same time, ADT guided for 2026 revenue and adjusted EPS to be approximately flat while targeting roughly 20% growth in adjusted free cash flow, underscoring a shift toward cash generation,...

Recent move in MKS stock MKS (MKSI) has caught investor attention after a recent pullback, with the stock down about 5% over the past day and 15% over the past month, despite what the company describes as strong multi year total returns. See our latest analysis for MKS. Looking past the recent pullback, MKS has a 90 day share price return of 37.05% and a year to date share price return of 26.81%, alongside a 1 year total shareholder return of 164.69%. This suggests that near term momentum is...

Why Mueller Industries is Drawing Attention Now Mueller Industries (MLI) is back on many watchlists after a period of relatively flat performance over the past 3 months. This has prompted investors to reassess its recent returns and fundamentals. See our latest analysis for Mueller Industries. At a share price of $113.91, Mueller Industries has seen recent pressure with a 7 day share price return of 4.04% and year to date share price return of 2.48%. However, its 1 year total shareholder...

Melco Resorts & Entertainment (MLCO) is back in the spotlight after unveiling its new City of Dreams chapter, Be A Dreamer, featuring Jing Boran as Global Brand Ambassador and Tan Yuan Yuan as Friend of the Brand. See our latest analysis for Melco Resorts & Entertainment. Despite the new Be A Dreamer launch and branding push in Macau, Melco Resorts & Entertainment’s 30 day share price return of 13.08% and 90 day share price return of 32.93% show fading momentum, even as the 1 year total...

If you are wondering whether Amicus Therapeutics at around US$14.37 is attractively priced or already reflecting a lot of optimism, you are in the right place to focus on what the numbers are actually saying about value. The stock's return profile, with 0.3% over the last 7 days, 0.5% over 30 days, 0.7% year to date and 61.6% over 1 year, suggests the market has been reassessing the company over different time frames. Recent news around Amicus Therapeutics has continued to center on its role...

In recent months, Kaiser Aluminum reported strong quarterly results and highlighted progress on its multi‑year capacity upgrades in aerospace and packaging, while acknowledging lower shipments tied to aerospace destocking and a slower-than-planned packaging coating line ramp. Institutional interest has risen, with funds such as Third Avenue Small‑Cap Value Fund increasing holdings and pointing to Kaiser Aluminum’s operational execution and capacity investments as key drivers of its current...

Custom Truck One Source (CTOS) is back in focus after reporting record Q4 2025 revenue of US$528.18 million, alongside strong rental fleet utilization and earnings that exceeded profit and adjusted EBITDA expectations. See our latest analysis for Custom Truck One Source. The recent Q4 2025 update and 2026 revenue guidance came after a weak 7 day share price return of 14.87% and a 30 day share price return of 12.90%, even though the 1 year total shareholder return sits at 26.00%, so momentum...

Assessing Laureate Education after recent share price moves Laureate Education (LAUR) has drawn attention after a recent pullback, with the stock down about 6% over the past month and modestly positive over the past 3 months. This has prompted fresh questions about its valuation. See our latest analysis for Laureate Education. At a share price of US$33.31, Laureate Education has recently seen a 2.37% 1 day share price pullback and a 5.93% 30 day share price decline. At the same time, its 1...

Why Extra Space Storage Is On Investors’ Radar Extra Space Storage (EXR) has been drawing attention after recent share moves, with a roughly flat month, a gain over the past 3 months, and a small decline over the past year. For investors watching income focused real estate, the stock’s current US$141.52 share price, value score of 2, and recent revenue and net income figures are helping frame expectations around risk and potential reward. See our latest analysis for Extra Space Storage. The...

If you are wondering whether Accenture's recent share price weakness has opened up a value opportunity, this article will walk through what the numbers actually say. The stock last closed at US$201.48, with returns of a 4.1% decline over 7 days, a 14.9% decline over 30 days, a 22.5% decline year to date and a 36.5% decline over 1 year, while the 3 year and 5 year returns are a 13.6% decline and a 17.4% decline respectively. Recent coverage around Accenture has focused on its position in...

In February 2026, Gibraltar Industries reported fourth-quarter and full-year 2025 results showing sales rising to US$268.69 million for the quarter and US$1.14 billion for the year, while moving from prior-year profits to a net loss alongside lower earnings per share from continuing operations. At the same time, the company issued ambitious 2026 guidance, projecting a sharp increase in net sales and outlining how the OmniMax acquisition and expected synergies could reshape its business mix...

Medical Properties Trust (MPT) has drawn investor attention after a prolonged share price slide, with the stock down about 10% over the past month and 4% over the past 3 months. See our latest analysis for Medical Properties Trust. The recent 10.36% 7 day share price decline and 9.71% 30 day share price return, along with a 1 year total shareholder return decline of 11.38% and a 65.86% decline over five years, suggests momentum has been weak and investor risk perceptions remain cautious. If...

Royalty Pharma (RPRX) drew fresh investor attention after appointing Kenneth Sun as Senior Vice President and Head of Asia, a move directly related to the company’s push into Asia’s royalty funding market. See our latest analysis for Royalty Pharma. The appointment of Kenneth Sun comes as Royalty Pharma’s share price has climbed to US$46.69, with a 30 day share price return of 5.99% and a 90 day share price return of 20.30%. Its 1 year total shareholder return of 45.51% and 3 year total...

FB Financial stock triggered by recent performance reset FB Financial (FBK) has come onto investors’ radar after a recent reset in its share performance, with the stock down over the past month and past 3 months despite a positive 1 year total return. See our latest analysis for FB Financial. At a share price of US$51.71, FB Financial’s recent 30 day and 90 day share price returns indicate fading short term momentum, even as its 1 year and 3 year total shareholder returns remain positive. If...

In recent days, Teladoc Health drew renewed attention after upbeat fourth‑quarter 2025 results, analyst upgrades from Deutsche Bank and BofA Securities, and insider share sales by its Chief Legal Officer, all amid continued focus on AI and international expansion. A key angle is the growing optimism around reshaping Teladoc’s BetterHelp mental health unit, which analysts now view as central to a potential turnaround. With analysts highlighting BetterHelp’s evolving role in Teladoc’s...

Why Bristol-Myers Squibb (BMY) is on investors’ radar today Bristol-Myers Squibb (BMY) has drawn attention after a recent move in its share price, with the stock closing at $59.98 and showing mixed returns over the past week, month, and past 3 months. See our latest analysis for Bristol-Myers Squibb. While the 1-day share price return of a 0.25% decline and 7-day share price return of a 3.77% decline point to some near-term cooling, the 90-day share price return of 17.15% and positive...

Olema Pharmaceuticals (OLMA) is back in focus after its stock dropped sharply following Roche’s failed Phase 3 trial for breast cancer drug giredestrant, which raised fresh questions around estrogen receptor targeted therapies. See our latest analysis for Olema Pharmaceuticals. The 1 day share price return of 0.95% is small compared with a 7 day share price decline of 35.87% and a 90 day drop of 50.57%. However, the 1 year total shareholder return of about 2.5x suggests recent selling has...

Lucid Group has begun rolling out Apple CarPlay and Android Auto via a complimentary over-the-air Lucid UX 3.5 update to Gravity SUVs in North America, with Middle East and Europe deployments scheduled for later in March, while all new Gravity models now include this smartphone integration as standard alongside Air sedans. This enhanced connectivity, combined with Lucid’s broader technology focus and upcoming Investor Day, underscores how software updates and partnerships are central to its...

Omnicom Group (NYSE:OMC) has agreed to acquire Interpublic Group, creating a new global advertising giant. The combined company brings together Omnicom's creative and analytics capabilities with Interpublic's agencies and client network. Investors are watching how this large scale merger might influence client strategy, digital offerings, and competitive positioning. For you as an investor, this is a significant moment for NYSE:OMC. Omnicom is a major global advertising and marketing...

Ameresco overview and recent performance snapshot Ameresco (AMRC) has been drawing attention after recent share price weakness, with the stock showing negative returns over the past week, month and past 3 months despite a positive 1 year total return. See our latest analysis for Ameresco. Recent trading has been weak, with a 30-day share price return of 20.21% and a 90-day share price return of 19.59% at a last close of US$25.82. This is despite the 1-year total shareholder return of 144.51%,...

Itron recently expanded its UtilityIQ Application Suite to support new Cellular 500G and 500W modules in the US, while Tantalus Systems extended its license agreement to maintain full compatibility with Itron’s legacy ERT metering technologies across the TRUConnect AMI platform. Together, these moves strengthen Itron’s role at the center of grid modernization by helping utilities bridge legacy metering assets with flexible, multi-transport AMI deployments. We’ll now examine how Itron’s...

Zoetis (NYSE:ZTS) is expanding its support for veterinary education by offering free Human Animal Bond Certification to veterinary technician students across the US. The program extends an existing scholarship initiative and now targets a broader segment of the veterinary care team. This move focuses on the relationship between people and animals, a core element of modern companion animal and livestock care. For investors watching NYSE:ZTS, this update fits within Zoetis’s role as a global...

Delek Logistics Partners, LP recently reported its fourth-quarter and full-year 2025 results, with quarterly revenue of US$255,770,000 and net income of US$47,290,000, and full-year revenue of US$1.01 billion and net income of US$176,460,000, all higher than the prior year. The partnership also delivered higher basic earnings per share from continuing operations for both the quarter and full year, suggesting improved efficiency in turning revenue into profit for unitholders. With this...

Tenaya Therapeutics (TNYA) is back in focus after reporting a full year 2025 net loss of US$90.6 million, alongside fresh preclinical data and a new collaboration in cardiovascular and muscular disease programs. See our latest analysis for Tenaya Therapeutics. The recent MDA 2026 data for TN-301 and the new Alnylam collaboration appear to have sharpened market focus, with a 7 day share price return of 47.70% standing in contrast to a 36.86% decline over 90 days and a 3 year total shareholder...